Skip to main content
Top
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Spirometry | Research article

FEV1 and total Cardiovascular mortality and morbidity over an 18 years follow-up Population-Based Prospective EPIC-NORFOLK Study

Authors: Siew-Mooi Ching, Yook-Chin Chia, Marleen A. H. Lentjes, Robert Luben, Nicholas Wareham, Kay-Tee Khaw

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

Our study aimed to determine the association between forced expiratory volume in one second (FEV1) and subsequent fatal and non-fatal events in a general population.

Methods

The Norfolk (UK) based European Prospective Investigation into Cancer (EPIC-Norfolk) recruited 25,639 participants between 1993 and 1997. FEV1 measured by portable spirometry, was categorized into sex-specific quintiles. Mortality and morbidity from all causes, cardiovascular disease (CVD) and respiratory disease were collected from 1997 up to 2015. Cox proportional hazard regression analysis was used with adjustment for socio-economic factors, physical activity and co-morbidities.

Results

Mean age of the population was 58.7 ± 9.3 years, mean FEV1 for men was 294± 74 cL/s and 214± 52 cL/s for women. The adjusted hazard ratios for all-cause mortality for participants in the highest fifth of the FEV1 category was 0.63 (0.52, 0.76) for men and 0.62 (0.51, 0.76) for women compared to the lowest quintile. Adjusted HRs for every 70 cL/s increase in FEV1 among men and women were 0.77 (p < 0.001) and 0.68 (p < 0.001) for total mortality, 0.85 (p<0.001) and 0.77 (p<0.001) for CVD and 0.52 (p <0.001) and 0.42 (p <0.001) for respiratory disease.

Conclusions

Participants with higher FEV1 levels had a lower risk of CVD and all-cause mortality. Measuring the FEV1 with a portable handheld spirometry measurement may be used as a surrogate marker for cardiovascular risk. Every effort should be made to identify those with poorer lung function even in the absence of cardiovascular disease as they are at greater risk of total and CV mortality.
Literature
1.
go back to reference Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–23 Epub 2014/01/30.CrossRefPubMed Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–23 Epub 2014/01/30.CrossRefPubMed
2.
go back to reference Rasmussen T, Kober L, Pedersen JH, Dirksen A, Thomsen LH, Stender S, et al. Relationship between chronic obstructive pulmonary disease and subclinical coronary artery disease in long-term smokers. Eur Heart J Cardiovasc Imaging. 2013;14(12):1159–66 Epub 2013/05/04.CrossRefPubMed Rasmussen T, Kober L, Pedersen JH, Dirksen A, Thomsen LH, Stender S, et al. Relationship between chronic obstructive pulmonary disease and subclinical coronary artery disease in long-term smokers. Eur Heart J Cardiovasc Imaging. 2013;14(12):1159–66 Epub 2013/05/04.CrossRefPubMed
3.
go back to reference Gan WQ, Man SP. Systemic effects and mortality in chronic obstructive pulmonary disease. stress. 2008;2:3. Gan WQ, Man SP. Systemic effects and mortality in chronic obstructive pulmonary disease. stress. 2008;2:3.
4.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti A. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–57.CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti A. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–57.CrossRefPubMed
5.
go back to reference Sunyer J, Ulrik CS. Level of FEV1 as a predictor of all-cause and cardiovascular mortality: an effect beyond smoking and physical fitness? Eur Respir J. 2005;25(4):587–8.CrossRefPubMed Sunyer J, Ulrik CS. Level of FEV1 as a predictor of all-cause and cardiovascular mortality: an effect beyond smoking and physical fitness? Eur Respir J. 2005;25(4):587–8.CrossRefPubMed
6.
go back to reference Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(Suppl 1):95–103. Epub 1999/08/31.PubMed Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(Suppl 1):95–103. Epub 1999/08/31.PubMed
7.
go back to reference Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(suppl 1):S6.CrossRefPubMed Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(suppl 1):S6.CrossRefPubMed
8.
go back to reference Chowienczyk P, Lawson C. Pocket-sized device for measuring forced expiratory volume in one second and forced vital capacity. BMJ. 1982;285(6334):15–7.CrossRefPubMed Chowienczyk P, Lawson C. Pocket-sized device for measuring forced expiratory volume in one second and forced vital capacity. BMJ. 1982;285(6334):15–7.CrossRefPubMed
9.
go back to reference Manning LS, Mistri AK, Potter J, Rothwell PM, Robinson TG. Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post stroke and continue or stop post-stroke antihypertensives collaborative study trials. Stroke. 2015;46(6):1518–24 Epub 2015/04/25.CrossRefPubMed Manning LS, Mistri AK, Potter J, Rothwell PM, Robinson TG. Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post stroke and continue or stop post-stroke antihypertensives collaborative study trials. Stroke. 2015;46(6):1518–24 Epub 2015/04/25.CrossRefPubMed
10.
go back to reference Shohaimi S, Boekholdt M, Luben R, Wareham N, Khaw K-T. Distribution of lipid parameters according to different socio-economic indicators- the EPIC-Norfolk prospective population study. BMC Public Health. 2014;14(1):782.CrossRefPubMedPubMedCentral Shohaimi S, Boekholdt M, Luben R, Wareham N, Khaw K-T. Distribution of lipid parameters according to different socio-economic indicators- the EPIC-Norfolk prospective population study. BMC Public Health. 2014;14(1):782.CrossRefPubMedPubMedCentral
11.
go back to reference Khaw K-T, Bingham S, Welch A, Luben R, Wareham N, Oakes S, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet. 2001;357(9257):657–63.CrossRefPubMed Khaw K-T, Bingham S, Welch A, Luben R, Wareham N, Oakes S, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet. 2001;357(9257):657–63.CrossRefPubMed
12.
go back to reference Shohaimi S, Welch A, Bingham S, Luben R, Day N, Wareham N, et al. Area deprivation predicts lung function independently of education and social class. Eur Respir J. 2004;24(1):157–61.CrossRefPubMed Shohaimi S, Welch A, Bingham S, Luben R, Day N, Wareham N, et al. Area deprivation predicts lung function independently of education and social class. Eur Respir J. 2004;24(1):157–61.CrossRefPubMed
13.
go back to reference Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407–13.CrossRefPubMed Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407–13.CrossRefPubMed
14.
go back to reference Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med. 2008;5(1):e12 Epub 2008/01/11.CrossRefPubMedPubMedCentral Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med. 2008;5(1):e12 Epub 2008/01/11.CrossRefPubMedPubMedCentral
15.
go back to reference Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–5 discussion 5-6. Epub 1996/09/21.CrossRefPubMedPubMedCentral Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–5 discussion 5-6. Epub 1996/09/21.CrossRefPubMedPubMedCentral
16.
go back to reference Shibata Y, Inoue S, Igarashi A, Yamauchi K, Abe S, Aida Y, et al. A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One. 2013;8(12):e83725 Epub 2013/12/19.CrossRefPubMedPubMedCentral Shibata Y, Inoue S, Igarashi A, Yamauchi K, Abe S, Aida Y, et al. A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One. 2013;8(12):e83725 Epub 2013/12/19.CrossRefPubMedPubMedCentral
17.
go back to reference Baughman P, Marott JL, Lange P, Martin CJ, Shankar A, et al. Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J Epidemiol. 2012;27:933–43.CrossRefPubMed Baughman P, Marott JL, Lange P, Martin CJ, Shankar A, et al. Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J Epidemiol. 2012;27:933–43.CrossRefPubMed
18.
go back to reference Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388–93.CrossRefPubMedPubMedCentral Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388–93.CrossRefPubMedPubMedCentral
19.
go back to reference Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, TM J. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64.CrossRefPubMed Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, TM J. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64.CrossRefPubMed
20.
go back to reference Sabia S, Shipley M, Elbaz A, Marmot M, Kivimaki M, Kauffmann F, et al. Why does lung function predict mortality? Results from the Whitehall II Cohort Study. Am J Epidemiol. 2010;172(12):1415–23 Epub 2010/10/22.CrossRefPubMedPubMedCentral Sabia S, Shipley M, Elbaz A, Marmot M, Kivimaki M, Kauffmann F, et al. Why does lung function predict mortality? Results from the Whitehall II Cohort Study. Am J Epidemiol. 2010;172(12):1415–23 Epub 2010/10/22.CrossRefPubMedPubMedCentral
21.
go back to reference Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study. Am J Epidemiol. 2014;179(1):48–56 Epub 2013/09/26.CrossRefPubMed Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study. Am J Epidemiol. 2014;179(1):48–56 Epub 2013/09/26.CrossRefPubMed
22.
go back to reference Kaptoge S, Di AE, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.CrossRefPubMed Kaptoge S, Di AE, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.CrossRefPubMed
23.
go back to reference Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax. 2007;62(6):515–20.CrossRefPubMedPubMedCentral Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax. 2007;62(6):515–20.CrossRefPubMedPubMedCentral
24.
go back to reference Kasayama S, Tanemura M, Koga M, Fujita K, Yamamoto H, Miyatake A. Asthma is an independent risk for elevation of plasma C-reactive protein levels. Clin Chim Acta. 2009;399(1–2):79–82.CrossRefPubMed Kasayama S, Tanemura M, Koga M, Fujita K, Yamamoto H, Miyatake A. Asthma is an independent risk for elevation of plasma C-reactive protein levels. Clin Chim Acta. 2009;399(1–2):79–82.CrossRefPubMed
25.
go back to reference Siafakas NM, Antoniou KM, Tzortzaki EG. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):453–62.PubMedPubMedCentral Siafakas NM, Antoniou KM, Tzortzaki EG. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):453–62.PubMedPubMedCentral
26.
go back to reference Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005;60(7):605–9.CrossRefPubMedPubMedCentral Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005;60(7):605–9.CrossRefPubMedPubMedCentral
27.
go back to reference Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–21.CrossRefPubMed Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–21.CrossRefPubMed
28.
29.
go back to reference Alfageme I, Reyes N, Merino M, Reina A, Gallego J, Lima J, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chronic respiratory disease. 2010;7(3):135–45. Epub 2010/08/07.CrossRefPubMed Alfageme I, Reyes N, Merino M, Reina A, Gallego J, Lima J, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chronic respiratory disease. 2010;7(3):135–45. Epub 2010/08/07.CrossRefPubMed
30.
go back to reference Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.CrossRefPubMed Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.CrossRefPubMed
31.
go back to reference O'Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299–310. Epub 2008/03/26. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study.CrossRefPubMed O'Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299–310. Epub 2008/03/26. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study.CrossRefPubMed
32.
go back to reference The Multiple Risk Factor Intervention Trial Group. Statistical design considerations in the NHLI. multiple risk factor intervention trial (MRFIT). J Chronic Dis. 1977;30:261–75.CrossRef The Multiple Risk Factor Intervention Trial Group. Statistical design considerations in the NHLI. multiple risk factor intervention trial (MRFIT). J Chronic Dis. 1977;30:261–75.CrossRef
33.
go back to reference Zhang H, Thijs L, Staessen JA. Blood Pressure Lowering for Primary and Secondary Prevention of Stroke. Hypertension. 2006;48(2):187–95.CrossRefPubMed Zhang H, Thijs L, Staessen JA. Blood Pressure Lowering for Primary and Secondary Prevention of Stroke. Hypertension. 2006;48(2):187–95.CrossRefPubMed
34.
go back to reference Pfister R, Michels G, Brägelmann J, Sharp SJ, Luben R, Wareham NJ, et al. Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. Int J Cardiol. 2014;177(3):830–5.CrossRefPubMed Pfister R, Michels G, Brägelmann J, Sharp SJ, Luben R, Wareham NJ, et al. Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. Int J Cardiol. 2014;177(3):830–5.CrossRefPubMed
35.
go back to reference Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality in never-smokers. J Clin Epidemiol. 1990;43(9):867–73.CrossRefPubMed Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality in never-smokers. J Clin Epidemiol. 1990;43(9):867–73.CrossRefPubMed
36.
go back to reference Sin DD, Man SP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.CrossRefPubMed Sin DD, Man SP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.CrossRefPubMed
37.
go back to reference Incalzi RA, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2794–800.CrossRef Incalzi RA, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2794–800.CrossRef
38.
go back to reference American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis. 1991;144(5):1202–18.CrossRef American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis. 1991;144(5):1202–18.CrossRef
39.
go back to reference Ching SM, Pang YK, Price D, et al. Detection of airflow limitation using a handheld spirometer in a primary care setting. Respirology. 2014;19(5):689–93.CrossRefPubMedPubMedCentral Ching SM, Pang YK, Price D, et al. Detection of airflow limitation using a handheld spirometer in a primary care setting. Respirology. 2014;19(5):689–93.CrossRefPubMedPubMedCentral
Metadata
Title
FEV1 and total Cardiovascular mortality and morbidity over an 18 years follow-up Population-Based Prospective EPIC-NORFOLK Study
Authors
Siew-Mooi Ching
Yook-Chin Chia
Marleen A. H. Lentjes
Robert Luben
Nicholas Wareham
Kay-Tee Khaw
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Spirometry
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-6818-x

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue